ijms-logo

Journal Browser

Journal Browser

Ovarian Cancer: Pathogenesis, Biomarkers and Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 462

Special Issue Editor


E-Mail Website
Guest Editor
Division of Gynecologic Oncology, Michele and Pietro Ferrero Hospital, Verduno, Italy
Interests: ovarian cancer; gynecological disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Ovarian cancer is a significant and often life-threatening disease that primarily affects the ovaries, which are the female reproductive organs responsible for producing eggs and hormones. It is one of the leading causes of cancer-related deaths among women.

Several distinct histotypes of epithelial ovarian carcinoma have been recognized, with the high-grade serous form being the most predominant. A better understanding of the biology and the molecular mechanisms underlying the aggressive advancement of this disease are imperative for pinpointing and establishing efficacious treatments which can elevate survival rates among ovarian cancer patients.

The focus of this Special Issue is to foster discourse on studies that delve into the innovative molecular mechanisms, pathways, and therapeutic approaches aimed at addressing ovarian cancer. We welcome contributions from researchers possessing pertinent experience in ovarian cancer research, whether in the form of original research papers or comprehensive review articles.

Dr. Alessandro Antonio Buda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • radiotherapy
  • diagnosis
  • prevention
  • treatment
  • fertility sparing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 3180 KiB  
Review
From Defense to Disease: How the Immune System Fuels Epithelial–Mesenchymal Transition in Ovarian Cancer
by Michał Kos, Paulina Mertowska, Sebastian Mertowski, Jacek Roliński, Aleksandra Krasińska-Płachta, Tomasz Urbanowicz, Marek Gogacz and Ewelina Grywalska
Int. J. Mol. Sci. 2025, 26(9), 4041; https://doi.org/10.3390/ijms26094041 - 24 Apr 2025
Viewed by 378
Abstract
Ovarian cancer is one of the most deadly gynecological cancers, with over 300 thousand new cases per year, most of which are diagnosed in advanced stages. The limited availability of effective biomarkers and lack of characteristic symptoms make early diagnosis difficult, resulting in [...] Read more.
Ovarian cancer is one of the most deadly gynecological cancers, with over 300 thousand new cases per year, most of which are diagnosed in advanced stages. The limited availability of effective biomarkers and lack of characteristic symptoms make early diagnosis difficult, resulting in a five-year survival rate of 30–40%. Mutations in the BRCA1 and BRCA2 genes and abnormalities of signaling pathways such as PI3K/AKT and TP53 play a key role in the progression of ovarian cancer. The immune system, which can act against tumors, often supports tumor development in the ovarian cancer microenvironment through immunoevasion, which is influenced by cytokines such as IL-6, IL-10, and TGF-β. Epithelial-to-mesenchymal transition (EMT) allows cancer cells to acquire mesenchymal characteristics, increasing their invasiveness and metastatic capacity. Immunological factors, including pro-inflammatory cytokines and signals from the tumor microenvironment regulate the EMT process. This review aims to present the role of EMT in ovarian cancer progression, its interactions with the immune system, and potential biomarkers and therapeutic targets. Modulation of the immune response and inhibition of EMT may constitute the basis for personalized therapies, which opens new possibilities for improving the prognosis and efficacy of treatment in patients with ovarian cancer. Full article
(This article belongs to the Special Issue Ovarian Cancer: Pathogenesis, Biomarkers and Treatment)
Show Figures

Figure 1

Back to TopTop